Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Auris Medical (EARS)

Auris Medical (EARS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 34,765
  • Shares Outstanding, K 11,417
  • Annual Sales, $ 174 K
  • Annual Income, $ -8,750 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 1.17
  • Price/Sales 96.49
  • Price/Cash Flow N/A
  • Price/Book 1.94
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 06/30/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.80 +8.75%
on 07/19/21
3.75 -18.80%
on 06/28/21
-0.46 (-13.25%)
since 06/23/21
3-Month
2.78 +9.53%
on 05/06/21
4.58 -33.52%
on 06/03/21
-0.29 (-8.83%)
since 04/23/21
52-Week
0.73 +319.71%
on 09/24/20
6.60 -53.86%
on 12/01/20
+2.04 (+202.99%)
since 07/23/20

Most Recent Stories

More News
Auris Medical Announces Launch of New Corporate Website

Hamilton, Bermuda, July 15, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and...

EARS : 3.05 (-1.77%)
Auris Medical Announces Publication of Data from Preclinical Studies with Bentrioâ„¢ Nasal Spray in Prevention and Mitigation of SARS-CoV-2

EARS : 3.05 (-1.77%)
Auris Medical to Develop KRAS-Targeting RNA Treatment for Colorectal Cancer as First Therapeutic Indication for OligoPhoreâ„¢ Technology

Hamilton, Bermuda, July 6, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and...

EARS : 3.05 (-1.77%)
Auris Medical to Initiate Market Launch of Bentrioâ„¢ Nasal Spray in Germany

Hamilton, Bermuda, June 28, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and...

EARS : 3.05 (-1.77%)
Auris Medical Announces Significant Inhibition of Tumor Growth with OligoPhore siRNA Targeting NF-κB in Murine Model of Adult T-Cell Leukemia / Lymphoma

Hamilton, Bermuda, June 21, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and...

EARS : 3.05 (-1.77%)
Auris Medical Announces Acquisition of RNA Therapeutics Company and Plans for Strategic Repositioning

EARS : 3.05 (-1.77%)
Auris Medical Starts Preparations for Covid-19 Trial with Bentrio in India

Hamilton, Bermuda, June 1, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology...

EARS : 3.05 (-1.77%)
Auris Medical Holding to Present at LD Micro Invitational XI Conference

Hamilton, Bermuda, May 28, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology...

EARS : 3.05 (-1.77%)
Auris Medical Announces Completion of Bentrio Conformity Assessment Procedure for Marketing in EU

Hamilton, Bermuda, May 25, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology...

EARS : 3.05 (-1.77%)
Auris Medical Reaches Midpoint for Enrollment in Part B of AM-125 Phase 2 TRAVERS Trial in Acute Peripheral Vertigo

Hamilton, Bermuda, May 14, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology...

EARS : 3.05 (-1.77%)

Business Summary

Auris Medical Holding AG is a biopharmaceutical company. It focuses on developing therapies for the treatment of hearing loss and tinnitus. The Company has two projects in advanced clinical development: AM-101 for the treatment of acute inner ear tinnitus and AM-111 for the treatment of acute inner ear...

See More

Key Turning Points

3rd Resistance Point 3.18
2nd Resistance Point 3.13
1st Resistance Point 3.09
Last Price 3.05
1st Support Level 3.00
2nd Support Level 2.96
3rd Support Level 2.91

See More

52-Week High 6.60
Fibonacci 61.8% 4.36
Fibonacci 50% 3.66
Last Price 3.05
Fibonacci 38.2% 2.97
52-Week Low 0.73

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar